Vial Initiates Phase 1 Trial of Novel INHBE siRNA Therapy for Obesity Treatment
核心洞察
Vial (搜索) has launched a first-in-human Phase 1 trial of VIAL-INHBE (搜索), a GalNAc-conjugated INHBE (Activin E (搜索)) siRNA designed to treat obesity with a projected six-month dosing interval.
Preclinical data in diet-induced obesity mouse models demonstrated fat-selective weight loss and lean mass preservation, with combination therapy using low-dose GLP-1 (搜索) showing synergistic effects.
The open-label study in Australia will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics, with interim data expected in the first half of 2026.
Vial (搜索), a clinical-stage biotechnology company, has initiated a Phase 1 trial for VIAL-INHBE (搜索), a novel INHBE (Activin E (搜索)) siRNA therapy targeting obesity and other cardiometabolic diseases. The first-in-human study represents a significant milestone for the San Francisco-based company's approach to addressing limitations in current obesity treatments.
Novel siRNA Approach Targets Activin E Pathway
VIAL-INHBE (搜索) is a GalNAc-conjugated INHBE (Activin E (搜索)) siRNA designed with a projected six-month dosing interval. The therapy targets the INHBE pathway, which plays a role in metabolic regulation and body composition. According to Simon Burns, CEO of Vial (搜索), "The initiation of the Phase 1 trial for Vial's INHBE siRNA program is a major milestone in advancing the program."
The Phase 1 trial is structured as a first-in-human, single-ascending dose study that will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous VIAL-INHBE (搜索) administration. The open-label study is being conducted in Australia, with interim subcutaneous safety and pharmacokinetic data expected in the first half of 2026.
Preclinical Data Shows Promise for Fat-Selective Weight Loss
Diet-induced obesity (DIO) mouse model studies demonstrated compelling results for VIAL-INHBE (搜索), showing fat-selective weight loss and lean mass preservation. The preclinical data support what the company describes as a potentially best-in-class profile relating to fat-selective weight loss, off-treatment weight maintenance, and dosing interval.
Particularly notable was the combination therapy approach tested in preclinical studies. When VIAL-INHBE (搜索) was combined with a low-dose GLP-1 (搜索) receptor agonist, the combination resulted in synergistic weight loss and lean mass preservation that was maintained even after GLP-1 treatment was discontinued.
Addressing Current Treatment Limitations
The development of VIAL-INHBE (搜索) is positioned to address significant gaps in the current obesity treatment landscape. As explained by Preeti Sareen, Ph.D., Head of Strategy at Vial (搜索), "GLP-1s have revolutionized the obesity treatment landscape, but there remain significant unmet needs: poor GI tolerability and associated high discontinuation rates, loss of lean mass, and weight regain post-GLP-1 (搜索) treatment."
The preclinical data suggest that VIAL-INHBE (搜索) combined with a lower, more tolerable GLP-1 (搜索) dose achieved similar total body weight loss as high-dose GLP-1 monotherapy, while preserving lean mass and attenuating weight rebound post-treatment.
Clinical Development Timeline
Following the completion of the Phase 1 trial, Vial (搜索) plans to initiate a multi-region Phase 2 trial in obesity later in 2026. The company expects to share interim data from the Phase 1 trial in the first half of 2026, which will provide initial insights into the safety and pharmacokinetic profile of the therapy in humans.
Vial (搜索), founded in 2020, has raised over $100 million to date from leading life sciences investors including General Catalyst, Buckley Ventures, and Byers Capital. The company is focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet medical need.